Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.
The potential for the development of resistance in oxacillin-resistant Staphylococcus aureus (ORSA) to lysostaphin, a glycylglycine endopeptidase produced by Staphylococcus simulans biovar staphylolyticus, was examined in vitro and in an in vivo model of infection. Following in vitro exposure of ORSA to subinhibitory concentrations of lysostaphin, lysostaphin-resistant mutants were idenitifed among all isolates examined. Resistance to lysostaphin was associated with a loss of resistance to beta-lactams and a change in the muropeptide interpeptide cross bridge from pentaglycine to a single glycine. Mutations in femA, the gene required for incorporation of the second and third glycines into the cross bridge, were found following PCR amplification and nucleotide sequence analysis. Complementation of lysostaphin-resistant mutants with pBBB31, which encodes femA, restored the phenotype of oxacillin resistance and lysostaphin susceptibility. Addition of beta-lactam antibiotics to lysostaphin in vitro prevented the development of lysostaphin-resistant mutants. In the rabbit model of experimental endocarditis, administration of a low dose of lysostaphin for 3 days led predictably to the appearance of lysostaphin-resistant ORSA mutants in vegetations. Coadministration of nafcillin with lysostaphin prevented the emergence of lysostaphin-resistant mutants and led to a mean reduction in aortic valve vegetation counts of 7.5 log(10) CFU/g compared to those for untreated controls and eliminated the isolation of lysostaphin-resistant mutants from aortic valve vegetations. Treatment with nafcillin and lysostaphin given alone led to mean reductions of 1.35 and 1.65 log(10) CFU/g respectively. In ORSA, resistance to lysostaphin was associated with mutations in femA, but resistance could be suppressed by the coadministration of beta-lactam antibiotics.
Climo
M W
MW
Department of Medicine, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, USA. Michael.Climo@med.va.gov
Ehlert
K
K
Archer
G L
GL
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics; D004347:Drug Interactions; D004352:Drug Resistance, Microbial / Q000235:genetics / Q000502:physiology; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D006801:Humans; D008248:Lysostaphin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation; D010068:Oxacillin / Q000494:pharmacology*; D010406:Penicillins / Q000494:pharmacology; D010455:Peptides; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; C096686:FemA protein, Bacteria; D010406:Penicillins; D010455:Peptides; D008248:Lysostaphin; D010068:Oxacillin